Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment

Context: Adjuvant chemotherapy is associated with significant reductions in bone mineral density (BMD) in premenopausal women with breast cancer (BC) that is prevented with zoledronic acid (ZA) every 3 months for 1 yr. Objective: The aim of the study was to examine the effect on BMD of discontinuing...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Hershman, Dawn L., McMahon, Donald J., Crew, Katherine D., Shao, Theresa, Cremers, Serge, Brafman, Lois, Awad, Danielle, Shane, Elizabeth
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The Endocrine Society 2010
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2840866/
https://ncbi.nlm.nih.gov/pubmed/20022990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2009-1366
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia